Vivalis
6 rue Alain-Bombard
Saint-Herblain
44800
France
Tel: 33-0-228-073710
Fax: 33-0-228-073711
Website: http://www.Vivalis.com/
Email: info@vivalis.com
60 articles about Vivalis
-
Vivalis to Buy Intercell AG in European Biotech Merger for $174 Million
12/17/2012
-
BioDiem Ltd. and Vivalis Begin Collaboration to Test Production of the LAIV Vector on the EB66® Cell Line
5/9/2012
-
Vivalis and GeoVax Labs Inc. Enter into a Biomanufacturing Agreement for the Production Of MVA-Based Vaccines for HIV
10/18/2011
-
Potential Treatment for Chikungunya Discovered, A*STAR and Vivalis Reveal
2/28/2011
-
Potential Treatment for Chikungunya Discovered by Collaboration between Vivalis and A*STAR's Singapore Immunology Network
2/15/2011
-
Vivalis, GlaxoSmithKline Win OK For First Human Trial With EB66
11/24/2010
-
Vivalis and Kitasato Sign a Research License to Evaluate Eb66(R) Cell Line for Human Viral Vaccine Production
10/12/2010
-
Vivalis Signs a New Evaluation Agreement for Protein Production in the EB66(R) Cell Line
10/5/2010
-
Vivalis Signs New Eb66 Research License With MYMETICS Corporation
9/28/2010
-
Vivalis Publishes Its Results For The First Half And Confirms 2010 Targets
8/31/2010
-
Vivalis Expands R&D Capacities And Moves Into A New Facility
6/23/2010
-
Vivalis Signs A New Commercial License Of The Eb66(R) Cell Line In The Veterinary Vaccine Field
6/15/2010
-
Vivalis Partners With Sanofi Pasteur For The Discovery Of Human Monoclonal Antibodies Against Infectious Diseases
6/8/2010
-
Vivalis Reports First Quarter 2010 Revenues
5/4/2010
-
Vivalis Files Its Annual Registration Document
4/22/2010
-
Vivalis Achieves Milestone With GlaxoSmithKline In The Development Of Human Flu Vaccines Based On Eb66
4/7/2010
-
Vivalis: A Solid Performance For 2009
4/6/2010
-
Vivalis Grants Research Licence To Kyoto Biken To Evaluate Eb66(R) Cell Line For Viral Vaccines Production
2/16/2010
-
Vivalis: 2009 Achievements And Pursuit Of Robust Growth In 2010
1/27/2010
-
Vivalis Announces the Strategic Acquisition of HUMALYS For EUR 10.4M (15.6M USD) and the Addition of a New Platform for Generating Human Monoclonal Antibodies
1/11/2010